Stem cell leading stock index refers to the stocks of listed companies with leading position and advantages in stem cell research and application. With the rapid development of biomedicine, stem cell technology is considered to have great potential and broad application prospects. What are the following listed companies with stem cell concept stocks? Let's take a look, hoping to bring some reference.

What are the listed companies of stem cell concept stocks?

1, Fosun Pharma (600 196): The company's main business is pharmaceutical manufacturing and research and development. According to the opening news on April 2 1 day, the growth rate of Fosun Pharma's performance dropped by -9.5 1% this year, and the latest price was 32.480 yuan, with a turnover of 497 million yuan.

2.AVIC Industry and Trade (600705): The company's main business is diversified financial business. On April 2 1 day, AVIC Financial's share price fell by 6.05% in five days. The latest price of the stock is 3.800 yuan, down 2.3 1%, with a turnover of 302 million yuan and a turnover rate of 0.89%.

3. Zhao Yan New Drugs (603 127): The company is engaged in preclinical research services of drugs and reproductive sales of experimental animals. On April 2 1 day, the latest price of new drugs in Zhao Yan was 53.570 yuan, and the stock price fell by 5. 13% within 3 days. Since the beginning of this year, the growth rate has dropped by -8.34% and the P/E ratio is 26.65.

4. International Medicine (0005 16): The company is engaged in medical services. According to the opening news on April 2 1 day, the share price of international medicine fell by 9.58% within 3 days, and the latest price was 10.650 yuan, with a turnover of 227 million yuan.

5. Tasly Force (600535): The company is engaged in modern Chinese medicine and chemical medicine. At the close of 15, Tasly reported 15.4 10 yuan, down 0.45%, with a total market value of 23 1. 1 100 million yuan.

6. Dongcheng Pharmaceutical Co., Ltd. (002675): The company's business includes raw materials, nuclear medicine and general preparations (chemicals and traditional Chinese medicines). On April 2 1 day, Dongcheng Pharmaceutical News 15 yuan rose by 0.26%, and its share price fell by 5.27% within three days, with a total market value of 1283 1 100 million yuan.

7. Nanjing Xinbai (600682): The company is mainly engaged in commercial retail. On April 2 1 day, Nanjing Xinbai reported a drop of-12.5% this year, with the latest price of 8. 160 yuan, down 1.2 1%, with a turnover of 68.7032 million yuan.

8. Zhenghai Bio (300653): The company is mainly engaged in research and development, production and sales of bio-renewable materials. According to the opening news on April 2 1 day, Zhenghai Bio's share price fell by 5.39% in five days, and this year's increase rose by 7.04%, with the latest report of 46.590 yuan, with a turnover of 7,546,438+0 million yuan.

Stem cell sector stock market value ranking

1, Fosun Pharma: 93.545 billion yuan.

By the close of 15, Fosun Pharma reported 35.040 yuan, down 2.83%, with a total market value of 93.545 billion yuan.

2. New drugs in Zhao Yan: 3 16438+0 billion yuan.

165438+1On October 25th, new drugs in Zhao Yan opened at 60.3 yuan and closed at 59. 160 yuan, down 2.42%. The highest price on that day was 60.3 yuan, and the lowest was 58.66 yuan, with 4229 1 000 lots, with a total market value of 3 1 696,5438+0,000,000 yuan.

3.AVIC industry and finance: 28.523 billion yuan.

165438+1October 25th, AVIC finance opened at 3. 18 yuan and closed at 3.230 yuan, up 1.57%. The highest price on that day was 3.24 yuan, and the lowest was 3. 17 yuan, with a total market value of 28.523 billion yuan.

4. International medicine: 25.46 billion yuan.

165438+1October 25th news, international medical opening quotation1.41yuan, closing 1 1. 190 yuan. The highest price of the day 1 1.44 yuan, the lowest 10.99 yuan, with a total market value of 25.46 billion yuan.

5. Tasly force: 17538+0 billion yuan.

1October 25th 165438+ closing news, Tasly's share price closed down 1.6%, the quotation1.7 10 yuan, and the market value reached1750.

6. Dongcheng Pharmaceutical: 65.438+03.828 billion yuan.

165438+ closing news1On October 25th, Dongcheng Pharmaceutical made an opening offer of 17.06 yuan and closed at 16.770 yuan. Within five days, the stock price fell by 7.04%, with a total market value of1382.8 billion yuan.

What are the leading stocks of stem cells?

Shengjitang: the leading stock of stem cells

165438+1the opening news on October 22nd showed that within three days, the share price of Shengjitang rose by 8.9%, the latest price was 3.260 yuan, and the turnover was1.90 billion yuan.

In order to support the normal development of the research and development project of new drugs for vector stem cells and provide convenient conditions for the next development of vector, the company plans to increase the capital of vector by 66 million yuan in cash.

Guan Hao Biology: Stem Cell Leading Unit

165438+1October 22nd, Guan Hao Bio closed at 15, and the stock newspaper 1 1.490 yuan, down 3.2%. In three days, the stock price fell by 3.3 1%, with a total market value of 3.047 billion yuan.

Since 20 13, the company has established a research and application platform for cells and stem cells, and has the only two cell production lines in China that have passed GMP on-site certification. The production line follows the "standardization and standardization" of GMP workshop, and follows the highest international standards in terms of safety and effectiveness of cell storage, which provides a model standard for establishing GMP certification system for cell production lines in the future.

Rongjie Health: Leading shares of stem cells

165438+1opening news on October 22nd, Rongjie Health recently reported 3.750 yuan, with 3 1855400 lots, with a total market value of 30150,000 yuan.

As one of the leading enterprises in China's big health industry, the company is committed to providing services for people's family health products, and has initially formed a service platform for people's "healthy life". The company has covered all kinds of health appliances such as basic health check-ups, "disease prevention" auxiliary products such as remote red physiotherapy rooms, massage chairs, massage gadgets and fitness equipment, as well as high-end health management services such as diagnosis and treatment of traditional Chinese medicine and stem cell biotechnology.

Other stem cell concept stocks include:

International medicine: the stock price rose by 4.78% in the past 5 days.

Sihuan Bio: The stock price fell 1.44% in recent 5 days and -6.34% in 2022.

Sue A: Looking back on the past five trading days, Sue A fell for three consecutive days. During the period, the overall decline was 2.79%, with the highest price of 5.38 yuan and the lowest price of 4.93 yuan, and the total turnover was 6102.120,000 lots.

Peking University Medicine: Looking back on the past five trading days, Peking University Medicine rose for four consecutive days. During the period, the overall increase was 4.89%, with the highest price of 10.39 yuan and the lowest price of 8.59 yuan, with a total turnover of 326 million lots.

List of leading stem cell stocks in 2023

1, Guan Hao Bio: leading stock.

In the second quarter of 2022, Guan Hao Biological Company mainly engaged in biological dura mater patch, neurosurgery equipment and accessories, Benvimod, etc. The revenue was 47.6835 million yuan, 4.65438+0.554/kloc-0.04 million yuan and 28.53 2853. 1.48 million yuan respectively, accounting for 23.5% and 20.48% respectively.

Guan Hao Bio released its financial report for the third quarter of 2022, achieving an operating income of 9110.7100000 yuan, a year-on-year increase of-16.87%, and a net profit of1240120000 yuan, a year-on-year increase of- Earnings per share is 0.05 yuan.

2. Shengjitang: leading stock

In the second quarter of 2022, Shengjitang Company mainly engaged in urea, methanol and compound fertilizer, with revenues of 778 million yuan, 378 million yuan and 65.438+29 million yuan, accounting for 56.43%, 27.4% and 9.39% respectively.

The financial report shows that in the third quarter of 2022, the company's operating income was 550 million yuan; The net profit attributable to listed shareholders is-65.438+0.27 billion yuan; Fully diluted net assets income-4.22%; Gross profit margin 1.45% and earnings per share -0.08 yuan.

3. Rongjie Health: Leading Shares

In the second quarter of 2022, Rongjie Health Company mainly engaged in far-infrared physiotherapy rooms, fitness equipment and air purifiers. , its income is 6.5438+39 million yuan, 26.8236 million yuan, 6.5438+062375 million yuan, accounting for 59.07%, 654.38+0 1.36% and 6.36% respectively.

Rongjie Health released its financial report for the third quarter of 2022, achieving an operating income of 94.5235 million yuan, a year-on-year increase of -4.88%, and a net profit of 37 1.3 1 10,000 yuan, a year-on-year increase of -82.7%.

4. Zhongyuan Concord: leading stock

In the second quarter of 2022, Zhongyuan Sheikh Company mainly engaged in detection reagents, cell detection preparation and storage, and scientific research reagents. , its income is 403 million yuan, 2 1 103 million yuan, accounting for 52.74%, 27.6% and 13.49% respectively.

Zhongyuan Concord released its financial report for the third quarter of 2022, achieving an operating income of 407 million yuan, up 4.0 1% year-on-year, and a net profit of 497 1.83 million yuan, up-37.94% year-on-year; Earnings per share is 0. 1 yuan.